4 results
To determine the safety and effectiveness of the PROMUS Element* Everolimus-Eluting Coronary Stent System (Boston Scientific Corporation [BSC], Natick, MA) for the treatment of patients with up to 2 de novo atherosclerotic lesions
The primary objective of this study is to evaluate the target lesion failure rate of the Conor Sirolimus-eluting Coronary Stent System in lesions up to 28 mm in length in native coronary arteries with a reference vessel diameter of 2.5 mm to 3.5 mm…
Primary Objective:* Assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions as indicated by proportion of population reporting with…
The objective of this clinical study is to prove the safety of the CorNeat KPro.